Higgons John Duncan 4
4 · Jounce Therapeutics, Inc. · Filed Jan 22, 2021
Insider Transaction Report
Form 4
Higgons John Duncan
Director
Transactions
- Sale
Common Stock
2021-01-20$12.00/sh−1,500$18,000→ 10,513 total - Sale
Common Stock
2021-01-21$11.11/sh−200$2,222→ 10,313 total
Footnotes (2)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 6, 2019. The Reporting Person exercised no discretion with respect to these transactions.
- [F2]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2020. The Reporting Person exercised no discretion with respect to these transactions.